vbi-1901
vbi vaccines
['gbm']
vbi vaccines presents updated phase 2a tumor response and overall survival data for vbi-1901 in recurrent gbm at the 2022 asco annual meeting - neuro central via brainsights for ios 
Stay on top of the latest Brain & Neuroscience research & news from all the best sources delivered directly to your iPhone/iPad